Literature DB >> 1735334

Gut hormones and gastrointestinal motility in children with cystic fibrosis.

M S Murphy1, A L Brunetto, A D Pearson, M A Ghatei, R Nelson, E J Eastham, S R Bloom, A A Green.   

Abstract

Intestinal dysmotility may be an important factor contributing to various gastrointestinal complications associated with cystic fibrosis. Motilin, enteroglucagon, neurotensin, and peptide YY may each play a role as endocrine hormones influencing gastrointestinal motor activity. Fasting children with cystic fibrosis (N = 8) and controls (N = 18) received a liquid nutrient test meal (fat 4 g/100 ml, protein 4 g/100 ml, carbohydrate 20 g/100 ml, 125 kcal/100 ml; 200 ml/m2) containing lactulose (5 g/100 ml), and the plasma concentrations of these peptides were studied. Mouth-to-cecum transit time was simultaneously studied using the breath H2 technique. Fasting levels of peptide YY and the postprandial response of all four peptides were significantly increased in those with cystic fibrosis. In repeat studies on those with cystic fibrosis after a period of altered pancreatic enzyme supplementation, no significant changes in peptide concentrations were observed. A rise in breath H2 permitting estimation of mouth-to-cecum transit time was noted in 17 control subjects (70-220 min, median 140). In contrast, a rise occurred in only two with cystic fibrosis after low-dose enzyme (70 and 180 min), and four after high-dose enzyme replacement (120-230 min, median 155). Altered gut hormone secretion may play a role in the pathophysiology of intestinal dysmotility in patients with cystic fibrosis.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1735334     DOI: 10.1007/bf01308170

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  25 in total

1.  Gastro-intestinal and nutritional aspects in CF and its relation with the respiratory system. Proceedings of a workshop. Rotterdam, The Netherlands.

Authors: 
Journal:  Acta Paediatr Scand Suppl       Date:  1985

2.  An enteroglucagon tumour.

Authors:  S R Bloom
Journal:  Gut       Date:  1972-07       Impact factor: 23.059

3.  Gut hormones in tropical malabsorption.

Authors:  H S Besterman; G C Cook; D L Sarson; N D Christofides; M G Bryant; M Gregor; S R Bloom
Journal:  Br Med J       Date:  1979-11-17

Review 4.  Gastrointestinal manifestations of cystic fibrosis: a review.

Authors:  R W Park; R J Grand
Journal:  Gastroenterology       Date:  1981-12       Impact factor: 22.682

5.  Investigation of small bowel transit time in man utilizing pulmonary hydrogen (H2) measurements.

Authors:  J H Bond; M D Levitt; R Prentiss
Journal:  J Lab Clin Med       Date:  1975-04

6.  The ileal brake--inhibition of jejunal motility after ileal fat perfusion in man.

Authors:  R C Spiller; I F Trotman; B E Higgins; M A Ghatei; G K Grimble; Y C Lee; S R Bloom; J J Misiewicz; D B Silk
Journal:  Gut       Date:  1984-04       Impact factor: 23.059

7.  Delayed small-intestinal transit in tropical malabsorption.

Authors:  G C Cook
Journal:  Br Med J       Date:  1978-07-22

8.  Peptide YY abnormalities in gastrointestinal diseases.

Authors:  T E Adrian; A P Savage; A J Bacarese-Hamilton; K Wolfe; H S Besterman; S R Bloom
Journal:  Gastroenterology       Date:  1986-02       Impact factor: 22.682

9.  Reversal of impaired GIP and insulin secretion in patients with pancreatogenic steatorrhea following enzyme substitution.

Authors:  R Ebert; W Creutzfeldt
Journal:  Diabetologia       Date:  1980-09       Impact factor: 10.122

10.  Increased plasma levels of peptide YY in coeliac disease.

Authors:  K Sjölund; R Ekman
Journal:  Scand J Gastroenterol       Date:  1988-04       Impact factor: 2.423

View more
  8 in total

Review 1.  Human pancreatic exocrine response to nutrients in health and disease.

Authors:  J Keller; P Layer
Journal:  Gut       Date:  2005-07       Impact factor: 23.059

2.  Electrogastrography in children with cystic fibrosis.

Authors:  Atiye Nur Aktay; Mark L Splaingard; Tami Miller; Mary Ellen Freeman; Heidi Hoeppner; Steven L Werlin
Journal:  Dig Dis Sci       Date:  2002-04       Impact factor: 3.199

3.  Gastric emptying and intestinal transit of pancreatic enzyme supplements in cystic fibrosis.

Authors:  C J Taylor; P G Hillel; S Ghosal; M Frier; S Senior; W B Tindale; N Read
Journal:  Arch Dis Child       Date:  1999-02       Impact factor: 3.791

4.  Bacterial overgrowth in the cystic fibrosis transmembrane conductance regulator null mouse small intestine.

Authors:  Oxana Norkina; Tim G Burnett; Robert C De Lisle
Journal:  Infect Immun       Date:  2004-10       Impact factor: 3.441

Review 5.  The cystic fibrosis intestine.

Authors:  Robert C De Lisle; Drucy Borowitz
Journal:  Cold Spring Harb Perspect Med       Date:  2013-09-01       Impact factor: 6.915

Review 6.  Understanding Cystic Fibrosis Comorbidities and Their Impact on Nutritional Management.

Authors:  Dhiren Patel; Albert Shan; Stacy Mathews; Meghana Sathe
Journal:  Nutrients       Date:  2022-02-28       Impact factor: 5.717

Review 7.  Choline in cystic fibrosis: relations to pancreas insufficiency, enterohepatic cycle, PEMT and intestinal microbiota.

Authors:  Wolfgang Bernhard
Journal:  Eur J Nutr       Date:  2020-08-14       Impact factor: 5.614

8.  Mast cells and gastrointestinal dysmotility in the cystic fibrosis mouse.

Authors:  Robert C De Lisle; Lauren Meldi; Eileen Roach; Maureen Flynn; Racquel Sewell
Journal:  PLoS One       Date:  2009-01-27       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.